Downloads: 1
Diff of
/html_files/27218632.html
[000000]
..
[c0f169]
Switch to unified view
| a | b/html_files/27218632.html | ||
|---|---|---|---|
| 1 | |||
| 2 | <!DOCTYPE html> |
||
| 3 | <html> |
||
| 4 | <head> |
||
| 5 | <meta charset="utf-8"> |
||
| 6 | <title>27218632 Visualization</title> |
||
| 7 | </head> |
||
| 8 | <body> |
||
| 9 | <h1>27218632 Visualization</h1> |
||
| 10 | <p><a href="main.html">Back to Main Page</a></p> |
||
| 11 | <div class="entities" style="line-height: 2.5; direction: ltr">A |
||
| 12 | <mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 13 | 50 |
||
| 14 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
||
| 15 | </mark> |
||
| 16 | - |
||
| 17 | <mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 18 | year |
||
| 19 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
||
| 20 | </mark> |
||
| 21 | |||
| 22 | <mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 23 | old |
||
| 24 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
||
| 25 | </mark> |
||
| 26 | |||
| 27 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 28 | man |
||
| 29 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span> |
||
| 30 | </mark> |
||
| 31 | with a history of |
||
| 32 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 33 | metastatic |
||
| 34 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 35 | </mark> |
||
| 36 | |||
| 37 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 38 | mucinous |
||
| 39 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 40 | </mark> |
||
| 41 | |||
| 42 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 43 | appendiceal |
||
| 44 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 45 | </mark> |
||
| 46 | |||
| 47 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 48 | adenocarcinoma |
||
| 49 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 50 | </mark> |
||
| 51 | |||
| 52 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 53 | presents |
||
| 54 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
||
| 55 | </mark> |
||
| 56 | for evaluation of a |
||
| 57 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 58 | desquamating |
||
| 59 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 60 | </mark> |
||
| 61 | |||
| 62 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 63 | rash |
||
| 64 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 65 | </mark> |
||
| 66 | on his |
||
| 67 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 68 | face |
||
| 69 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 70 | </mark> |
||
| 71 | that has spread to his |
||
| 72 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 73 | scalp |
||
| 74 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 75 | </mark> |
||
| 76 | , |
||
| 77 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 78 | inguinal |
||
| 79 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 80 | </mark> |
||
| 81 | |||
| 82 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 83 | region |
||
| 84 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 85 | </mark> |
||
| 86 | , and |
||
| 87 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 88 | perineum |
||
| 89 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 90 | </mark> |
||
| 91 | |||
| 92 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 93 | over |
||
| 94 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 95 | </mark> |
||
| 96 | |||
| 97 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 98 | the |
||
| 99 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 100 | </mark> |
||
| 101 | |||
| 102 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 103 | past |
||
| 104 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 105 | </mark> |
||
| 106 | |||
| 107 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 108 | 4 |
||
| 109 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 110 | </mark> |
||
| 111 | |||
| 112 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 113 | months |
||
| 114 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 115 | </mark> |
||
| 116 | (Figure 1).</br>The |
||
| 117 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 118 | rash |
||
| 119 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 120 | </mark> |
||
| 121 | has been accompanied by |
||
| 122 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 123 | diffuse |
||
| 124 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 125 | </mark> |
||
| 126 | |||
| 127 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 128 | alopecia |
||
| 129 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 130 | </mark> |
||
| 131 | of the |
||
| 132 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 133 | face |
||
| 134 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 135 | </mark> |
||
| 136 | , |
||
| 137 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 138 | scalp |
||
| 139 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 140 | </mark> |
||
| 141 | , |
||
| 142 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 143 | axilla |
||
| 144 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 145 | </mark> |
||
| 146 | , and |
||
| 147 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 148 | groin |
||
| 149 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 150 | </mark> |
||
| 151 | .</br>There was no improvement in the |
||
| 152 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 153 | rash |
||
| 154 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 155 | </mark> |
||
| 156 | despite |
||
| 157 | <mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 158 | multiple |
||
| 159 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
||
| 160 | </mark> |
||
| 161 | |||
| 162 | <mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 163 | rounds |
||
| 164 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
||
| 165 | </mark> |
||
| 166 | of |
||
| 167 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 168 | oral |
||
| 169 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
||
| 170 | </mark> |
||
| 171 | |||
| 172 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 173 | fluconazole |
||
| 174 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 175 | </mark> |
||
| 176 | , |
||
| 177 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 178 | topical |
||
| 179 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
||
| 180 | </mark> |
||
| 181 | |||
| 182 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 183 | antibiotic |
||
| 184 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 185 | </mark> |
||
| 186 | |||
| 187 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 188 | ointment |
||
| 189 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
||
| 190 | </mark> |
||
| 191 | , and |
||
| 192 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 193 | intravenous |
||
| 194 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
||
| 195 | </mark> |
||
| 196 | |||
| 197 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 198 | antibiotics |
||
| 199 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 200 | </mark> |
||
| 201 | .</br>Prior to the development of his rash, he completed |
||
| 202 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 203 | neoadjuvant |
||
| 204 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 205 | </mark> |
||
| 206 | |||
| 207 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 208 | chemotherapy |
||
| 209 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 210 | </mark> |
||
| 211 | followed by |
||
| 212 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 213 | surgical |
||
| 214 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 215 | </mark> |
||
| 216 | |||
| 217 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 218 | resection |
||
| 219 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 220 | </mark> |
||
| 221 | .</br>He underwent |
||
| 222 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 223 | colostomy |
||
| 224 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 225 | </mark> |
||
| 226 | after he failed |
||
| 227 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 228 | surgical |
||
| 229 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 230 | </mark> |
||
| 231 | |||
| 232 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 233 | correction |
||
| 234 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 235 | </mark> |
||
| 236 | for an |
||
| 237 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 238 | enterocutaneous |
||
| 239 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 240 | </mark> |
||
| 241 | |||
| 242 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 243 | fistula |
||
| 244 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 245 | </mark> |
||
| 246 | , and he has required |
||
| 247 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 248 | total |
||
| 249 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 250 | </mark> |
||
| 251 | |||
| 252 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 253 | parenteral |
||
| 254 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 255 | </mark> |
||
| 256 | |||
| 257 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 258 | nutrition |
||
| 259 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 260 | </mark> |
||
| 261 | ( |
||
| 262 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 263 | TPN |
||
| 264 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 265 | </mark> |
||
| 266 | ) for the |
||
| 267 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 268 | past |
||
| 269 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 270 | </mark> |
||
| 271 | |||
| 272 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 273 | year |
||
| 274 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 275 | </mark> |
||
| 276 | .</br>He did not notice any significant |
||
| 277 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 278 | changes |
||
| 279 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 280 | </mark> |
||
| 281 | |||
| 282 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 283 | in |
||
| 284 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 285 | </mark> |
||
| 286 | |||
| 287 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 288 | ostomy |
||
| 289 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 290 | </mark> |
||
| 291 | |||
| 292 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 293 | output |
||
| 294 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 295 | </mark> |
||
| 296 | during this time.</br> |
||
| 297 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 298 | Dermatological |
||
| 299 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 300 | </mark> |
||
| 301 | |||
| 302 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 303 | examination |
||
| 304 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 305 | </mark> |
||
| 306 | reveals |
||
| 307 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 308 | widespread |
||
| 309 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 310 | </mark> |
||
| 311 | |||
| 312 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 313 | erythematous |
||
| 314 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 315 | </mark> |
||
| 316 | |||
| 317 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 318 | plaques |
||
| 319 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 320 | </mark> |
||
| 321 | on the |
||
| 322 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 323 | face |
||
| 324 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 325 | </mark> |
||
| 326 | , |
||
| 327 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 328 | scalp |
||
| 329 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 330 | </mark> |
||
| 331 | , and |
||
| 332 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 333 | medial |
||
| 334 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 335 | </mark> |
||
| 336 | |||
| 337 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 338 | aspect |
||
| 339 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 340 | </mark> |
||
| 341 | |||
| 342 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 343 | of |
||
| 344 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 345 | </mark> |
||
| 346 | |||
| 347 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 348 | thighs |
||
| 349 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 350 | </mark> |
||
| 351 | |||
| 352 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 353 | bilaterally |
||
| 354 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 355 | </mark> |
||
| 356 | and |
||
| 357 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 358 | scattered |
||
| 359 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 360 | </mark> |
||
| 361 | |||
| 362 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 363 | papules |
||
| 364 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 365 | </mark> |
||
| 366 | with |
||
| 367 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 368 | scaling |
||
| 369 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 370 | </mark> |
||
| 371 | on |
||
| 372 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 373 | face |
||
| 374 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 375 | </mark> |
||
| 376 | , |
||
| 377 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 378 | scalp |
||
| 379 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 380 | </mark> |
||
| 381 | , |
||
| 382 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 383 | chest |
||
| 384 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 385 | </mark> |
||
| 386 | , and |
||
| 387 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 388 | back |
||
| 389 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 390 | </mark> |
||
| 391 | .</br> |
||
| 392 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 393 | Diffuse |
||
| 394 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 395 | </mark> |
||
| 396 | , |
||
| 397 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 398 | non |
||
| 399 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 400 | </mark> |
||
| 401 | - |
||
| 402 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 403 | scarring |
||
| 404 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 405 | </mark> |
||
| 406 | |||
| 407 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 408 | alopecia |
||
| 409 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 410 | </mark> |
||
| 411 | is present on the |
||
| 412 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 413 | face |
||
| 414 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 415 | </mark> |
||
| 416 | , |
||
| 417 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 418 | scalp |
||
| 419 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 420 | </mark> |
||
| 421 | , |
||
| 422 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 423 | axillae |
||
| 424 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 425 | </mark> |
||
| 426 | , and |
||
| 427 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 428 | groin |
||
| 429 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 430 | </mark> |
||
| 431 | .</br>The patient had acquired |
||
| 432 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 433 | AE |
||
| 434 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 435 | </mark> |
||
| 436 | , a rare dermatologic condition caused by |
||
| 437 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 438 | zinc |
||
| 439 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 440 | </mark> |
||
| 441 | |||
| 442 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 443 | deficiency |
||
| 444 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 445 | </mark> |
||
| 446 | .</br>This patient developed |
||
| 447 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 448 | acquired |
||
| 449 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 450 | </mark> |
||
| 451 | |||
| 452 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 453 | zinc |
||
| 454 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 455 | </mark> |
||
| 456 | |||
| 457 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 458 | deficiency |
||
| 459 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 460 | </mark> |
||
| 461 | in the setting of |
||
| 462 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 463 | inadequate |
||
| 464 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 465 | </mark> |
||
| 466 | |||
| 467 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 468 | zinc |
||
| 469 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 470 | </mark> |
||
| 471 | |||
| 472 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 473 | supplementation |
||
| 474 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 475 | </mark> |
||
| 476 | in |
||
| 477 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 478 | TPN |
||
| 479 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 480 | </mark> |
||
| 481 | .</br>The patient had not received |
||
| 482 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 483 | trace |
||
| 484 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 485 | </mark> |
||
| 486 | |||
| 487 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 488 | elements |
||
| 489 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 490 | </mark> |
||
| 491 | for approximately |
||
| 492 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 493 | one |
||
| 494 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 495 | </mark> |
||
| 496 | |||
| 497 | <mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 498 | year |
||
| 499 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
||
| 500 | </mark> |
||
| 501 | due to a |
||
| 502 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 503 | national |
||
| 504 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Other_event</span> |
||
| 505 | </mark> |
||
| 506 | |||
| 507 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 508 | shortage |
||
| 509 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Other_event</span> |
||
| 510 | </mark> |
||
| 511 | .</br>The key to the correct diagnosis of acquired AE is the combination of desquamating rash coupled with alopecia in the setting of chronic supplemental alimentation.</br>Although it is reasonable to consider a skin biopsy, a skin biopsy would not definitively establish the diagnosis.</br>A paraneoplastic panel could be considered, but it would delay diagnosis, and the presentation is most consistent with nutritional deficiency.</br>It is not appropriate to start a topical steroid cream until a diagnosis is determined.</br>The patient had a |
||
| 512 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 513 | zinc |
||
| 514 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 515 | </mark> |
||
| 516 | level of |
||
| 517 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 518 | 29 |
||
| 519 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 520 | </mark> |
||
| 521 | |||
| 522 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 523 | ug/dL |
||
| 524 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 525 | </mark> |
||
| 526 | (normal range 56-134 ug/dL).</br>He received |
||
| 527 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 528 | zinc |
||
| 529 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 530 | </mark> |
||
| 531 | |||
| 532 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 533 | supplementation |
||
| 534 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 535 | </mark> |
||
| 536 | in his |
||
| 537 | <mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 538 | TPN |
||
| 539 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
||
| 540 | </mark> |
||
| 541 | , and within |
||
| 542 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 543 | one |
||
| 544 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 545 | </mark> |
||
| 546 | |||
| 547 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 548 | month |
||
| 549 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 550 | </mark> |
||
| 551 | , the patient had complete resolution of |
||
| 552 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 553 | rash |
||
| 554 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 555 | </mark> |
||
| 556 | and |
||
| 557 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 558 | fatigue |
||
| 559 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 560 | </mark> |
||
| 561 | , and gradual return of |
||
| 562 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 563 | hair |
||
| 564 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 565 | </mark> |
||
| 566 | |||
| 567 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 568 | growth |
||
| 569 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 570 | </mark> |
||
| 571 | (Figure 2).</br>Repeat |
||
| 572 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 573 | zinc |
||
| 574 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 575 | </mark> |
||
| 576 | |||
| 577 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 578 | level |
||
| 579 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 580 | </mark> |
||
| 581 | following supplementation was |
||
| 582 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 583 | 90 |
||
| 584 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 585 | </mark> |
||
| 586 | ug/dL.</br>Although the patient recovered from his |
||
| 587 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 588 | zinc |
||
| 589 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 590 | </mark> |
||
| 591 | |||
| 592 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 593 | deficiency |
||
| 594 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 595 | </mark> |
||
| 596 | , he later |
||
| 597 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 598 | passed |
||
| 599 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Outcome</span> |
||
| 600 | </mark> |
||
| 601 | |||
| 602 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 603 | away |
||
| 604 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Outcome</span> |
||
| 605 | </mark> |
||
| 606 | .</br></div> |
||
| 607 | </body> |
||
| 608 | </html> |
||
| 609 |